Combination therapy for resistant Sjögren's in children
Part of Blood & lymphatic, Bones, joints & muscles, Cancer, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests a combination of two medicines, rituximab then belimumab, for children and teens with Sjögren's syndrome that hasn't improved with other treatments. The goal is to see if this two-step approach can better control symptoms like joint pain, skin rashes, and blood problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 5 and 18 years old.
- You must have been diagnosed with Sjögren's syndrome (a condition that causes dry eyes and mouth, and can affect other parts of the body).
- You must have tried at least two other medicines or prednisone combined with another immune medicine for more than 3 months, and still have symptoms like joint pain, skin rashes, low blood counts, or organ involvement.
- You must agree to take both rituximab and belimumab (two biologic drugs that work on the immune system).
- You cannot have taken rituximab in the last 6 months, or ever taken belimumab or similar drugs before.
- You cannot have active infections (such as hepatitis B or C, HIV, tuberculosis) or a recent serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
This trial studies whether rituximab alone can help children with new-onset idiopathic nephrotic syndrome. It compares the treatment approach in order to see if it improves kidney recovery and reduces disease activity.
This study tests a combination of two medicines, rituximab and low-dose mycophenolate, to treat a type of kidney inflammation called proliferative lupus nephritis in children. It aims to see if the combination works well and is safe for kids with active lupus affecting the kidneys.
This trial tests rituximab, a medicine that affects the immune system, in children who have their first episode of steroid-sensitive nephrotic syndrome and are in remission at enrollment. It aims to see whether rituximab helps prevent relapse and improves kidney outcomes with fewer steroid needs.
This trial studies a new treatment called YTS109 for children aged 5 to 18 with certain autoimmune diseases that have not gotten better with standard therapies. The treatment targets and possibly removes a type of immune cell that may be causing the disease.
This trial tests whether adding rituximab to standard chemotherapy works better for children and teens with aggressive B-cell non-Hodgkin lymphoma. It may be a good option if your child's cancer cells have the CD20 protein and they haven't been treated with rituximab before.
Hear when a new Sjogren's Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.